|Combo: Protein & vector vaccines
|Study Start Date:
|Study Made Public:
A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX B/E®) Boosting in HIV-uninfected Thai Adults
RV144 (the Thai trial) is a Phase III, placebo-controlled, clinical trial to assess the efficacy of immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E to prevent HIV infection.
Sign in to see full information about this study and to download study data.